View ValuationThis company is no longer activeThe company may no longer be operating, as it may be out of business. Find out why through their latest events.See Latest EventsFile Forge Technology 将来の成長Future 基準チェック /06現在、 File Forge Technologyの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Capital Markets 収益成長10.9%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Jun 06Amirose London Limited completed the acquisition of File Forge Technology Plc (OFEX:FILE) in a reverse merger transaction.Amirose London Limited signed non-binding Heads of Terms to acquire File Forge Technology Plc (OFEX:FILE) for £0.07 million in a reverse merger transaction on March 20, 2025. The consideration consists of common equity of File Forge Technology Plc having a value of £5.01 million to be issued for common equity of Amirose London Limited. As part of consideration, £5.01 million is paid towards common equity of Amirose London Limited. Amirose London Limited executed a share purchase agreement to acquire File Forge Technology Plc (OFEX:FILE) for £0.07 million in a reverse merger transaction on April 25, 2025. File Forge has issued 100.190739 million shares to the shareholders of Amirose for £0.05 per New Ordinary Share. Amirose is seeking a listing on the Aquis Stock Exchange Growth Market via the reverse takeover in order to facilitate investments by investors and raise its profile with existing and future customers. Under the terms of the Acquisition Agreement, the Company will acquire Amirose through the issue of the Consideration Shares at an agreed valuation of £5,009,536. The Acquisition is conditional, inter alia, on the approval at the Extraordinary General Meeting of: i. the Waiver Resolution; ii. the Resolution to approve the Acquisition; and iii. the Resolutions to authorize the issue of the Consideration Shares and the Subscription Shares. Pursuant to the Acquisition and conditional on the approval of the Resolutions, all Directors will resign, and the Proposed Directors will be appointed on Admission. Michael Heath, Chief Executive Director, Aleksandra Binkowska, Non-Executive Chairperson, Mitchell Field, Non-Executive Director and David Battle, Independent Non-Executive Director. The Company has agreed with the Panel that Howard White, Ben White, Aleksandra Binkowska and Mitchell Field are ‘acting in concert’ in relation to the proposed acquisition by the Company of Amirose. Completion of the Acquisition was made subject to and conditional upon the satisfaction of certain conditions such conditions are required to be satisfied by no later than the long stop date, which has been agreed to be June 30, 2025. The transaction is subject to approval of offer by File Forge shareholders. It is expected that upon completion of the Proposed Acquisition, File Forge's name will be changed to Amirose London Holdings PLC. As of May 16, 2025 File Forge Technology's shareholder approved the transaction. As of May 21, 2025, On Admission, File Forge Technology PLC is to change its name to Amirose London Holdings PLC. Alfred Henry Corporate Finance Limited acted as financial advisor to File Forge Technology Plc and has charged £50,000 as advisor fees in the transaction. Glaisyers Solicitors LLP acted as legal advisor to File Forge Technology Plc. Computershare Investors Services (BVI) Ltd. Acted as registrar to File Forge Technology Plc. Amirose London Limited completed the acquisition of File Forge Technology Plc (OFEX:FILE) in a reverse merger transaction on June 6, 2025. The Company's change of name to Amirose London Holdings PLC will be effective once Companies House has issued a new certificate of incorporation reflecting the change of name. The ticker 'ALH' is effective immediately. From 9 June 2025, the Company's enlarged issued ordinary share capital will comprise 118,783,865 Ordinary Shares.お知らせ • Mar 21File Forge Technology Plc (OFEX:FILE) signed a letter of intent to acquire Amirose London Limited from Epoque Services Incorporated Limited for £5 million.File Forge Technology Plc (OFEX:FILE) signed non-binding Heads of Terms to acquire Amirose London Limited from Epoque Services Incorporated Limited for £5 million on March 20, 2025. The consideration consists of common equity of File Forge Technology Plc having a value of £5.01 million to be issued for common equity of Amirose London Limited. As part of consideration, £5.01 million is paid towards common equity of Amirose London Limited. The transaction is subject to approval of offer by File Forge shareholders. It is expected that upon completion of the Proposed Acquisition, File Forge's name will be changed to Amirose London Holdings PLC.New Risk • Mar 16New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended May 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m. Market cap is less than US$10m (UK£208.0k market cap, or US$269.1k). Minor Risk Latest financial reports are more than 6 months old (reported May 2024 fiscal period end).お知らせ • May 25Clarify Pharma PLC, Annual General Meeting, Jun 24, 2024Clarify Pharma PLC, Annual General Meeting, Jun 24, 2024. Location: the offices of fladgate llp, 16 great queen street, england, wc2b 5dg, london United KingdomNew Risk • Mar 18New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended May 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue is less than US$1m. Market cap is less than US$10m (UK£683.6k market cap, or US$870.4k). Minor Risk Latest financial reports are more than 6 months old (reported May 2023 fiscal period end).お知らせ • Jun 14Clarify Pharma PLC, Annual General Meeting, Jul 05, 2023Clarify Pharma PLC, Annual General Meeting, Jul 05, 2023, at 10:00 Coordinated Universal Time. Location: at the offices of Lomas & Co, Bridge House, 12 Market Street, Glossop, Derbyshire SK13 8AR London United KingdomBoard Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. was the last director to join the board, commencing their role in . The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • May 07Clarify Pharma PLC, Annual General Meeting, May 30, 2022Clarify Pharma PLC, Annual General Meeting, May 30, 2022, at 10:00 Coordinated Universal Time. Location: offices of Fladgate LLP, 16 Great Queen Street London United Kingdom このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、File Forge Technology は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測OFEX:FILE - アナリストの将来予測と過去の財務データ ( )GBP Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数5/31/2024N/A-100N/A2/29/2024N/A-100N/A11/30/2023N/A-100N/A8/31/2023N/A-100N/A5/31/2023N/A-1-1-1N/A2/28/2023N/A-1-1-1N/A11/30/2022N/A-1-1-1N/A8/31/2022N/A-1-1-1N/A5/31/2022N/A-1-1-1N/A2/28/2022N/A-1-1-1N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: FILEの予測収益成長が 貯蓄率 ( 2.5% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: FILEの収益がUK市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: FILEの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: FILEの収益がUK市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: FILEの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: FILEの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YDiversified-financials 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/06/05 07:59終値2025/06/05 00:00収益2024/05/31年間収益2023/11/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋File Forge Technology Plc 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Jun 06Amirose London Limited completed the acquisition of File Forge Technology Plc (OFEX:FILE) in a reverse merger transaction.Amirose London Limited signed non-binding Heads of Terms to acquire File Forge Technology Plc (OFEX:FILE) for £0.07 million in a reverse merger transaction on March 20, 2025. The consideration consists of common equity of File Forge Technology Plc having a value of £5.01 million to be issued for common equity of Amirose London Limited. As part of consideration, £5.01 million is paid towards common equity of Amirose London Limited. Amirose London Limited executed a share purchase agreement to acquire File Forge Technology Plc (OFEX:FILE) for £0.07 million in a reverse merger transaction on April 25, 2025. File Forge has issued 100.190739 million shares to the shareholders of Amirose for £0.05 per New Ordinary Share. Amirose is seeking a listing on the Aquis Stock Exchange Growth Market via the reverse takeover in order to facilitate investments by investors and raise its profile with existing and future customers. Under the terms of the Acquisition Agreement, the Company will acquire Amirose through the issue of the Consideration Shares at an agreed valuation of £5,009,536. The Acquisition is conditional, inter alia, on the approval at the Extraordinary General Meeting of: i. the Waiver Resolution; ii. the Resolution to approve the Acquisition; and iii. the Resolutions to authorize the issue of the Consideration Shares and the Subscription Shares. Pursuant to the Acquisition and conditional on the approval of the Resolutions, all Directors will resign, and the Proposed Directors will be appointed on Admission. Michael Heath, Chief Executive Director, Aleksandra Binkowska, Non-Executive Chairperson, Mitchell Field, Non-Executive Director and David Battle, Independent Non-Executive Director. The Company has agreed with the Panel that Howard White, Ben White, Aleksandra Binkowska and Mitchell Field are ‘acting in concert’ in relation to the proposed acquisition by the Company of Amirose. Completion of the Acquisition was made subject to and conditional upon the satisfaction of certain conditions such conditions are required to be satisfied by no later than the long stop date, which has been agreed to be June 30, 2025. The transaction is subject to approval of offer by File Forge shareholders. It is expected that upon completion of the Proposed Acquisition, File Forge's name will be changed to Amirose London Holdings PLC. As of May 16, 2025 File Forge Technology's shareholder approved the transaction. As of May 21, 2025, On Admission, File Forge Technology PLC is to change its name to Amirose London Holdings PLC. Alfred Henry Corporate Finance Limited acted as financial advisor to File Forge Technology Plc and has charged £50,000 as advisor fees in the transaction. Glaisyers Solicitors LLP acted as legal advisor to File Forge Technology Plc. Computershare Investors Services (BVI) Ltd. Acted as registrar to File Forge Technology Plc. Amirose London Limited completed the acquisition of File Forge Technology Plc (OFEX:FILE) in a reverse merger transaction on June 6, 2025. The Company's change of name to Amirose London Holdings PLC will be effective once Companies House has issued a new certificate of incorporation reflecting the change of name. The ticker 'ALH' is effective immediately. From 9 June 2025, the Company's enlarged issued ordinary share capital will comprise 118,783,865 Ordinary Shares.
お知らせ • Mar 21File Forge Technology Plc (OFEX:FILE) signed a letter of intent to acquire Amirose London Limited from Epoque Services Incorporated Limited for £5 million.File Forge Technology Plc (OFEX:FILE) signed non-binding Heads of Terms to acquire Amirose London Limited from Epoque Services Incorporated Limited for £5 million on March 20, 2025. The consideration consists of common equity of File Forge Technology Plc having a value of £5.01 million to be issued for common equity of Amirose London Limited. As part of consideration, £5.01 million is paid towards common equity of Amirose London Limited. The transaction is subject to approval of offer by File Forge shareholders. It is expected that upon completion of the Proposed Acquisition, File Forge's name will be changed to Amirose London Holdings PLC.
New Risk • Mar 16New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended May 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m. Market cap is less than US$10m (UK£208.0k market cap, or US$269.1k). Minor Risk Latest financial reports are more than 6 months old (reported May 2024 fiscal period end).
お知らせ • May 25Clarify Pharma PLC, Annual General Meeting, Jun 24, 2024Clarify Pharma PLC, Annual General Meeting, Jun 24, 2024. Location: the offices of fladgate llp, 16 great queen street, england, wc2b 5dg, london United Kingdom
New Risk • Mar 18New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended May 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue is less than US$1m. Market cap is less than US$10m (UK£683.6k market cap, or US$870.4k). Minor Risk Latest financial reports are more than 6 months old (reported May 2023 fiscal period end).
お知らせ • Jun 14Clarify Pharma PLC, Annual General Meeting, Jul 05, 2023Clarify Pharma PLC, Annual General Meeting, Jul 05, 2023, at 10:00 Coordinated Universal Time. Location: at the offices of Lomas & Co, Bridge House, 12 Market Street, Glossop, Derbyshire SK13 8AR London United Kingdom
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. was the last director to join the board, commencing their role in . The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • May 07Clarify Pharma PLC, Annual General Meeting, May 30, 2022Clarify Pharma PLC, Annual General Meeting, May 30, 2022, at 10:00 Coordinated Universal Time. Location: offices of Fladgate LLP, 16 Great Queen Street London United Kingdom